JUN and prostate cancer: The reduction in total c-Jun protein levels by aschantin treatment resulted in inhibition of c-Jun/AP-1 transactivation activity and suppression of cell growth in MIAPaCa-2 pancreas and LNCaP prostate cancers [12].